Welcome to our dedicated page for China Sxt Pharmaceuticals SEC filings (Ticker: SXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The China SXT Pharmaceuticals, Inc. (SXTC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. China SXT is a specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces (TCMPs) and Traditional Chinese Medicine Homologous Supplements (TCMHS), with operations based in Taizhou, Jiangsu, China and revenue generated from the People’s Republic of China, as described in its public documents.
China SXT files annual reports on Form 20-F and current reports on Form 6-K, along with registration statements such as Form F-3 for securities offerings. For example, a Form 6-K details the company’s 2025 special meeting of shareholders and the approval of a dual-class share structure, creating Class B Ordinary Shares with fifty votes per share and re-designating existing ordinary shares as Class A Ordinary Shares. Other filings reference the use of a shelf registration statement on Form F-3 for a registered direct offering of Class A ordinary shares (or pre-funded warrants in lieu thereof).
Through this page, users can review how China SXT reports changes in its capital structure, including share consolidations and the adoption of amended and restated memorandum and articles of association, as well as documents related to special shareholder meetings. Real-time updates from the SEC’s EDGAR system are combined with AI-powered summaries that explain the key points of lengthy filings, helping readers understand the implications of forms such as 20-F, 6-K, and F-3 without reading every page.
Investors and researchers can use the SXTC filings page to examine the company’s governance arrangements, voting rights, listing-related disclosures, and details of registered offerings, all as presented in its official SEC submissions.
China SXT Pharmaceuticals, Inc. submitted a Form 3 identifying Pan Xiaodong Sean, the company’s Chief Financial Officer, as a reporting person. The data provided shows no buy, sell, or derivative transactions, with all transaction counts and share amounts reported as zero.
China SXT Pharmaceuticals, Inc. director and Co-CEO Zhou Feng Felix filed an initial ownership report showing indirect holdings of the company’s equity. The filing reports 4 Class B Ordinary Shares held through Feng Zhou Management Limited, a British Virgin Islands company 100% owned and controlled by Feng Zhou.
China SXT Pharmaceuticals, Inc. director Chee Yong Lip filed an initial Form 3 as a reporting person. This filing serves as a baseline disclosure of his status as an insider of the company. The submission does not report any stock transactions or holdings in this excerpt.
China SXT Pharmaceuticals, Inc. director Ji Xiaodong has filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes a company insider. The provided data shows no reported transactions, no listed holdings, and no derivative positions associated with this filing.
China SXT Pharmaceuticals, Inc. director Liu Tong Tony has filed a Form 3, which is the initial statement of beneficial ownership of the company’s securities. This filing formally records his status as a reporting person and establishes the baseline for any future insider transaction disclosures.
China SXT Pharmaceuticals, Inc. filed an initial ownership report (Form 3) for Simon Lim Sze Beng, who serves as Co-Chief Executive Officer. This filing lists him as an officer but shows no reported share transactions, derivative positions, or current holdings in the data provided.
China SXT Pharmaceuticals, Inc. director Zheng Jun has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing’s transaction summary shows zero buy, sell, acquire, dispose, or derivative transactions, indicating no reportable trading activity in this submission.
China SXT Pharmaceuticals, Inc. is offering 2,000,000 Class A Ordinary Shares directly to investors at $0.38 per share pursuant to a Securities Purchase Agreement dated April 7, 2026, for gross proceeds of $760,000. The company will use net proceeds for working capital, development and commercialization of projects, and general corporate purposes.
The company is a BVI holding company that conducts operations through PRC subsidiaries and a VIE, which the prospectus highlights as a material risk because VIE agreements have not been court-tested in China. The filing reiterates risks from PRC regulatory change and HFCAA-related inspection uncertainty, states current auditor inspection status, and shows Class A shares listed on Nasdaq under "SXTC."
China SXT Pharmaceuticals, Inc. entered into a securities purchase agreement with investors to sell 2,000,000 Class A Ordinary Shares, raising approximately $760,000 in gross proceeds. The shares are being issued under an effective Form F-3 shelf registration and a related prospectus supplement.
The offering is expected to close on April 9, 2026, subject to customary closing conditions. The company plans to use the net proceeds for general corporate purposes, which typically includes funding operations or other routine business needs.
China SXT Pharmaceuticals completed a registered direct offering involving 12,000,000 Class A ordinary shares and pre-funded warrants to purchase 54,666,666 Class A ordinary shares. The company received approximately $9,110,000 in net proceeds after placement and other offering expenses and plans to use the cash for general corporate purposes. The pre-funded warrants are exercisable at $0.001 per share, may be exercised on a cash or cashless basis, and include a 9.99% beneficial ownership cap so a holder cannot exceed that ownership level through exercise. Univest Securities, LLC acted as exclusive placement agent and was paid a 7.0% cash fee on gross proceeds, a 0.5% non-accountable expense allowance, and up to $100,000 of out-of-pocket costs.